Rheumatoid Arthritis Blood Test (14-3-3eta) Data to be Presented at the World’s Premier Arthritis Conference
VANCOUVER, Oct. 25, 2013 /PRNewswire/ – Augurex Life Sciences Corp. announced today the expansion of key data related
to its innovative 14-3-3eta biomarkers with scheduled presentations
next week at the prestigious American College of Rheumatology Annual
Meeting, taking place at the San Diego Convention Center, October
25-30, 2013. World-leading investigators will present data, including a
late-breaking study, describing 14-3-3eta’s clinical utility for
rheumatoid arthritis (RA) patient management.
Together with its clinical collaborators, Augurex has presented data at
the annual meetings of the American College of Rheumatology and the
European League Against Rheumatism over the past 4 years describing its
panel of 14-3-3eta blood tests. These measure various aspects and forms
of the 14-3-3eta protein and inform RA diagnosis, prognosis and therapy
monitoring along the disease course. The field of rheumatology is
moving towards early identification and treatment of RA to improve patient clinical outcomes of this otherwise chronic
and debilitative autoimmune disease. The schedule for 14-3-3eta
presentations at the San Diego Convention Center is as follows.
_______________________________________________________________ |Title |Date/Time |Location | |__________________________|____________________|_______________| |91% of Early RA Patients |Oral Presentation |Hilton-Indigo D| |are Positive for Serum |Oct. 28, 4:30p-6:00p| | |14-3-3eta or its | | | |Auto-Antibodies (Abstract | | | |1786) | | | |Presenter: W. P. | | | |Maksymowych | | | |__________________________|____________________|_______________| |Serum 14-3-3eta Precedes |Oct. 28, 8:30a-4:00p|Exhibit Hall | |and Independently Predicts| |B2-C-D | |the Development of RA | | | |(Abstract 1389) | | | |Presenter: D. van | | | |Schaardenburg | | | |__________________________|____________________|_______________| |14-3-3eta and its |Oct. 28, 8:30a-4:00p|Exhibit Hall | |Auto-Antibodies Predict | |B2-C-D | |Response to Anti-TNF | | | |Therapy (Abstract 1315) | | | |Presenter: W. P. | | | |Maksymowych | | | |__________________________|____________________|_______________| |Chaperonin Protein 14-3-3n|Oct. 28, 8:30a-4:00p|Exhibit Hall | |(eta) in Rheumatoid | |B2-C-D | |Arthritis and | | | |Arthritogenic Viral | | | |Infections | | | |Presenter: S. J. Naides | | | |(Quest Diagnostics) | | | |__________________________|____________________|_______________| |Serum 14-3-3eta Marks RA |Late-Breaking |Exhibit Hall | |Development in Arthralgia |Oct 27- Oct 29, |B2-C-D | |and Radiographic |8:30a-4:00p | | |Progression in Early RA | | | |Patients (Abstract L13) | | | |Presenter: D. van | | | |Schaardenburg | | | |__________________________|____________________|_______________|
In April 2013, Quest Diagnostics (NYSE: DGX), the world’s leading provider of diagnostic information services, introduced two lab-developed tests to clinicians and patients in the United States
based on an exclusive license agreement with Augurex to the 14-3-3eta
marker. The new services aid the early diagnosis of RA, with one test
service providing results of 14-3-3eta blood levels, while a
comprehensive panel provides results of blood levels of 14-3-3eta as
well as the conventional RA markers cyclic citrullinated peptide (CCP)
antibodies and rheumatoid factor (RF).
Augurex expects 14-3-3eta to soon be available to clinicians and
patients in Canada and other major market countries through regional
partnerships with leading diagnostic companies.
SOURCE Augurex Life Sciences Corp.